Wai Yuen Tong Medicine (HKG:0897) expects an attributable profit of up to HK$3 million for the six months ended Sept. 30, down from HK$23.7 million a year prior, a Monday Hong Kong bourse filing said.
The drug company attributed the forecast to a 7% drop in revenue, a significant decline in net gains on the disposal of properties, and a reduction in net fair value gains on investment properties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.